Determining Pattern of Recurrence Following Pancreaticoduodenectomy and Adjuvant 5-Flurouracil-Based Chemoradiation Therapy: Effect of Number of Metastatic Lymph Nodes and Lymph Node Ratio

[1]  A. Jimeno,et al.  A Phase I Tolerability and Pharmacokinetic Study of Adjuvant Erlotinib (E) and Capecitabine (Cap) with Concurrent Radiation (RT) in Resected Pancreatic Cancer (PanCa) , 2008 .

[2]  K. Campbell,et al.  Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  R. Abrams,et al.  Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. , 2008, JAMA.

[4]  M. Choti,et al.  Impact of Total Lymph Node Count and Lymph Node Ratio on Staging and Survival after Pancreatectomy for Pancreatic Adenocarcinoma: A Large, Population-Based Analysis , 2007, Annals of Surgical Oncology.

[5]  Jeffrey E. Lee,et al.  Impact of Resection Status on Pattern of Failure and Survival After Pancreaticoduodenectomy for Pancreatic Adenocarcinoma , 2007, Annals of surgery.

[6]  M. Choti,et al.  Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. , 2007, Surgery.

[7]  K. Griffith,et al.  External-beam radiotherapy for localized extrahepatic cholangiocarcinoma. , 2006, International journal of radiation oncology, biology, physics.

[8]  M. Sierzega,et al.  The Ratio of Metastatic/Resected Lymph Nodes is an Independent Prognostic Factor in Patients With Node-positive Pancreatic Head Cancer , 2006, Pancreas.

[9]  A. Muratore,et al.  Pancreatic Resections after Chemoradiotherapy for Locally Advanced Ductal Adenocarcinoma: Analysis of Perioperative Outcome and Survival , 2006, Annals of Surgical Oncology.

[10]  J. Tepper,et al.  Adjuvant gemcitabine and concurrent radiation for patients with resected pancreatic cancer: a phase II study , 2006, British Journal of Cancer.

[11]  P. Philip,et al.  A Multi-Institutional Phase II Trial of Preoperative Full-Dose Gemcitabine and Concurrent Radiation for Patients With Potentially Resectable Pancreatic Carcinoma , 2006, Annals of Surgical Oncology.

[12]  Jeffrey E. Lee,et al.  Feasibility of a randomized trial of extended lymphadenectomy for pancreatic cancer. , 2005, Archives of surgery.

[13]  D. Gouma,et al.  Recurrent disease after microscopically radical (r0) resection of periampullary adenocarcinoma in patients without adjuvant therapy , 2004, Journal of Gastrointestinal Surgery.

[14]  C. Mcginn,et al.  Adjuvant therapy in pancreatic cancer: Phase I trial of radiation dose escalation with concurrent full-dose gemcitabine. , 2004, International journal of radiation oncology, biology, physics.

[15]  H. Jeekel.  Prognostic factors following curative resection for pancreatic adenocarcinoma. , 2004, Annals of surgery.

[16]  Jay Burmeister,et al.  Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer. , 2004, International journal of radiation oncology, biology, physics.

[17]  M. Knapton,et al.  Can routine laboratory data guide empirical prescribing? , 2004, Journal of clinical pathology.

[18]  Helen Hickey,et al.  A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. , 2004, The New England journal of medicine.

[19]  E. Ross,et al.  The Metastatic/Examined Lymph Node Ratio is an Important Prognostic Factor after Pancreaticoduodenectomy for Pancreatic Adenocarcinoma , 2004, The American surgeon.

[20]  D. Kerr,et al.  Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial , 2001, The Lancet.

[21]  K. Lillemoe,et al.  Resected adenocarcinoma of the pancreas— 616 patients: Results, outcomes, and prognostic indicators , 2000, Journal of Gastrointestinal Surgery.

[22]  G. Benassai,et al.  Significance of lymph node metastases in the surgical management of pancreatic head carcinoma. , 1999, Journal of experimental & clinical cancer research : CR.

[23]  M. Talamini,et al.  Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. , 1997, Annals of surgery.

[24]  Jeffrey E. Lee,et al.  Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Y. Ogata,et al.  Aggressive surgery for pancreatic duct cell cancer: Feasibility, validity, limitations , 1995, World Journal of Surgery.

[26]  Toshiya Takeda,et al.  An evaluation of radical resection for pancreatic cancer based on the mode of recurrence as determined by autopsy and diagnostic imaging , 1993, Cancer.

[27]  A. Andrén-sandberg,et al.  Recurrence of exocrine pancreatic cancer--local or hepatic? , 1993, Hepato-gastroenterology.

[28]  C. Pasquali,et al.  CA 19‐9 as a prognostic index after resection for pancreatic cancer , 1993, Journal of surgical oncology.

[29]  E. Rosato,et al.  Adjuvant therapy of resected adenocarcinoma of the pancreas. , 1991, International journal of radiation oncology, biology, physics.

[30]  J. Paradelo,et al.  Patterns of failure after curative resection of pancreatic carcinoma , 1990, Cancer.

[31]  Birgir Gudjonsson,et al.  Cancer of the pancreas: 50 years of surgery , 1987, Cancer.

[32]  J. Tepper,et al.  Carcinoma of the pancreas: Review of MGH experience from 1963 to 1973—Analysis of surgical failure and implications for radiation therapy , 1976, Cancer.

[33]  F. Mícek.  [Cancer of the pancreas]. , 1965, Bratislavske lekarske listy.

[34]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.

[35]  Jeffrey E. Lee,et al.  Neoadjuvant Chemoradiotherapy for Adenocarcinoma of the Pancreas: Treatment Variables and Survival Duration , 2001, Annals of Surgical Oncology.

[36]  C. Gebhardt,et al.  Prognostic factors in the operative treatment of ductal pancreatic carcinoma , 2000, Langenbeck's Archives of Surgery.

[37]  S. Lipsitz,et al.  Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology Group Study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  Ralph H. Hruban,et al.  Surgical pathology dissection : an illustrated guide , 1996 .

[39]  R. Hruban,et al.  Surgical Pathology Dissection , 1996, Springer New York.

[40]  Gastrointestinal Tumor Study Group Intraperitoneal Therapy Workshop. Proceedings of an International Symposium. March 16-17, 1985. Orlando, Florida. , 1985, Seminars in oncology.